Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott H Kaufmann

Showing results (1-10 of 267) with videos related to

Pageof 27
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2006
Imatinib spells BAD news for Bcr/abl-positive leukemiasScott H Kaufmann
Journal of Molecular Biology|August 23, 2025
Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and FutureAnnapoorna Venkatachalam, Scott H Kaufmann
Oncology (Williston Park, N.Y.)|March 2, 2010
Development of PARP inhibitors: an unfinished storyAnand Patel, Scott H Kaufmann
Cell Research|June 28, 2023
How CHKing ROS signaling preserves genomic integrityAnnapoorna Venkatachalam, Scott H Kaufmann
Current Treatment Options in Oncology|August 19, 2006
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignanciesThomas E Witzig, Scott H Kaufmann
Oncogene|October 25, 2003
Alterations in the apoptotic machinery and their potential role in anticancer drug resistanceScott H Kaufmann, David L Vaux
Genes & Development|February 21, 2012
Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumorsGregory J Gores, Scott H Kaufmann
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Prospects for the Use of ATR Inhibitors to Treat CancerJill M Wagner, Scott H Kaufmann
Science (New York, N.Y.)|November 6, 2010
Cancer. Targeting bacteria to improve cancer therapyAnand G Patel, Scott H Kaufmann
Elife|December 21, 2012
How does doxorubicin work?Anand G Patel, Scott H Kaufmann
Pageof 27

Showing results (1-10 of 267) with videos related to

Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2006
Imatinib spells BAD news for Bcr/abl-positive leukemiasScott H Kaufmann
Journal of Molecular Biology|August 23, 2025
Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and FutureAnnapoorna Venkatachalam, Scott H Kaufmann
Oncology (Williston Park, N.Y.)|March 2, 2010
Development of PARP inhibitors: an unfinished storyAnand Patel, Scott H Kaufmann
Cell Research|June 28, 2023
How CHKing ROS signaling preserves genomic integrityAnnapoorna Venkatachalam, Scott H Kaufmann
Current Treatment Options in Oncology|August 19, 2006
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignanciesThomas E Witzig, Scott H Kaufmann
Oncogene|October 25, 2003
Alterations in the apoptotic machinery and their potential role in anticancer drug resistanceScott H Kaufmann, David L Vaux
Genes & Development|February 21, 2012
Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumorsGregory J Gores, Scott H Kaufmann
Pharmaceuticals (Basel, Switzerland)|October 8, 2016
Prospects for the Use of ATR Inhibitors to Treat CancerJill M Wagner, Scott H Kaufmann
Science (New York, N.Y.)|November 6, 2010
Cancer. Targeting bacteria to improve cancer therapyAnand G Patel, Scott H Kaufmann
Elife|December 21, 2012
How does doxorubicin work?Anand G Patel, Scott H Kaufmann
Pageof 27